Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2023-02-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于作废部分已授予尚未归属的2021年限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the cancellation of a portion of previously granted but unvested 2021 restricted stock awards. It details board and supervisory meetings, independent director opinions, legal opinions, and the procedural background of the stock incentive plan. The content focuses on corporate governance and equity incentive plan adjustments rather than financial results or report publication. The document length is relatively short (2314 characters) and it is a formal announcement about a corporate action related to stock incentives, not a full report or financial statement. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a corporate governance matter that does not fit other specific categories like Remuneration Information or Share Issue/Capital Change, since it is about cancellation of granted restricted stock rather than issuance or compensation details.
2023-02-09 Chinese
上海市通力律师事务所关于深圳微芯生物科技股份有限公司2021年限制性股票及股票增值权激励计划第一个归属期及行权期符合归属条件及行权条件及作废部分已授予尚未归属的限制性股票或股票增值权相关事之法律意见书
Regulatory Filings
2023-02-09 Chinese
关于债券持有人减持公司可转换公司债券的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the reduction of holdings in the company's convertible bonds by certain bondholders, including the actual controller and related parties. It details the number of bonds held before and after the reduction, the percentage of total issuance, and the transaction dates. There is no indication of a full financial report, audit, or management discussion. The content focuses on a transaction involving the company's own convertible bonds, specifically a reduction in holdings by insiders. This fits the category of a Transaction in Own Shares (POS), as it reports on the company's convertible bonds being sold by insiders, which is akin to share transactions by directors or related parties.
2023-01-19 Chinese
自愿披露关于公司产品西格列他钠新纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the inclusion of their product, Chiglitazar Sodium, into the National Medical Insurance Directory (2022 edition). It discusses the product details, regulatory approval, impact on the company, and risk warnings. The document is relatively short (1521 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an official announcement about a regulatory and product status update rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-19 Chinese
股东减持股份计划公告
Major Shareholding Notification Classification · 95% confidence The document is a shareholder announcement regarding a plan to reduce shareholdings by specific shareholders. It details the number of shares held, the planned reduction quantities, methods, timing, and related risk disclosures. There is no financial data, earnings information, or management discussion of results. The document is a formal announcement of a shareholding reduction plan by shareholders, which fits the category of Major Shareholding Notification (MRQ). The document length is 3609 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2023-01-13 Chinese
关于可转债投资者适当性要求的风险提示性公告
Regulatory Filings Classification · 95% confidence The document is a risk warning announcement related to convertible bonds issued by Shenzhen Microchip Biotechnology Co., Ltd. It discusses the issuance details, regulatory approvals, trading codes, and the risk that certain investors not meeting suitability requirements cannot convert bonds into shares. The document is short (1340 characters) and primarily serves as a public notice or announcement rather than a detailed financial report or presentation. It does not contain financial statements, management discussion, or detailed financial data. It also references the full prospectus published earlier on the exchange website. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about bond issuance and investor suitability risks, not a full report or financial statement.
2023-01-09 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.